Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

Inclusion Criteria:

- Exon 19 deletion or Exon 21 L858R or L861Q or exon 18 G719X or S7681 EGFR mutation
positive NSCLC patients, or ALK rearranged NSCLC patients previously treated with a
tyrosine kinase inhibitor with progressive and measurable disease.

- Tumor tissue for PD-L1 assessment should be available unless PD-L1 assessment results
are already available.

- Patients should not have received any systemic chemotherapy for advanced NSCLC.
Patients who have received neoadjuvant, adjuvant or as part of concurrent chemotherapy
and radiation are eligible if they received the chemotherapy 12 months or more before
the start of study therapy.

- ECOG PS 0-1 (Eastern Cooperative Oncology Group Performance Status: an attempt to
quantify cancer patients' general well-being and activities of daily life. The score
ranges from 0 to 5 where 0 is asymptomatic and 5 is death.)

- Patients should have recovered to ≤ grade 1 from clinically meaningful (example
alopecia is not considered clinically meaningful) adverse events related to prior
treatments.

- Patients should be willing and able to provide written informed consent for the trial.

- Be ≥ 18 years of age on day of signing informed consent.

- Demonstrate adequate organ function

- Female subject of childbearing potential should have a negative urine or serum
pregnancy within 1 week of enrollment.

- Female subjects of childbearing potential must be willing to use an adequate method of
contraception

- Male subjects of child bearing potential must agree to use an adequate method of
contraception

Exclusion Criteria:

- Is currently participating and receiving study therapy or has participated in a study
of an investigational agent and received study therapy or used an investigational
device within 4 weeks of the first dose of treatment. If the half-life of the drug is
known then starting therapy 5 half-lives after the end of the last therapy is
acceptable.

- Has a diagnosis of immunodeficiency. Patient should not be of any immunosuppressive
therapy or steroids > prednisone 10mg/day or its equivalent on the day of the start of
therapy.

- Has a known history of active TB (Bacillus Tuberculosis)

- Hypersensitivity to pembrolizumab, carboplatin or pemetrexed or any of its excipients.

- Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study
Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events
due to agents administered more than 4 weeks earlier.

- Has had targeted small molecule therapy, or palliative radiation therapy within 1 week
prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from
adverse events due to a previously administered agent.

- Has a known additional malignancy that is progressing or requires active treatment or
the treating physician believes will require therapy within 1 year.

- Has symptomatic central nervous system (CNS) metastases and/or carcinomatous
meningitis.

- Has active autoimmune disease that has required systemic treatment in the past 2 years

- Has known history of non-infectious pneumonitis that required steroids or has current
pneumonitis. Has known history of interstitial lung disease.

- Has an active infection requiring systemic therapy.

- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the trial, interfere with the subject's
participation for the full duration of the trial, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator.

- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.

- Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 120 days after the last dose of trial treatment.

- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

- Has known active Hepatitis B or Hepatitis C

- Has received a live vaccine within 30 days of planned start of study therapy.